Inhibrx Biosciences
Stock Forecast, Prediction & Price Target
Inhibrx Biosciences Financial Estimates
Inhibrx Biosciences Revenue Estimates
Inhibrx Biosciences EBITDA Estimates
Inhibrx Biosciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $7.12M N/A | $2.17M -69.43% | $1.8M -17.35% | Avg: $1.99M Low: $1.99M High: $1.99M avg. 10.83% | Avg: $121.95M Low: $121.95M High: $121.95M avg. 6013.18% | Avg: $337.85M Low: $337.85M High: $337.85M avg. 177.02% | Avg: $346.75M Low: $346.75M High: $346.75M avg. 2.63% |
Net Income
% change YoY
| $-81.76M N/A | $-145.22M -77.60% | $-241.36M -66.19% | Avg: $-360.58M Low: $-290.79M High: $-174.85M avg. -49.39% | Avg: $-296.44M Low: $-237.53M High: $-237.53M avg. 17.78% | Avg: $-114.52M Low: $-114.52M High: $-114.52M avg. 61.36% | Avg: $-160.24M Low: $-160.24M High: $-160.24M avg. -39.91% |
EBITDA
% change YoY
| $-76.56M N/A | $-129.11M -68.63% | $-206.69M -60.08% | Avg: $-1.99M Low: $-1.99M High: $-1.99M avg. 99.03% | Avg: $-121.95M Low: $-121.95M High: $-121.95M avg. -6013.18% | Avg: $-337.85M Low: $-337.85M High: $-337.85M avg. -177.02% | Avg: $-346.75M Low: $-346.75M High: $-346.75M avg. -2.63% |
EPS
% change YoY
| -$2.15 N/A | -$3.62 -68.37% | -$5.12 -41.43% | Avg: -$4.94 Low: -$6.17 High: -$3.71 avg. 3.51% | Avg: -$5.04 Low: -$5.04 High: -$5.04 avg. -2.02% | Avg: -$2.43 Low: -$2.43 High: -$2.43 avg. 51.78% | Avg: -$3.4 Low: -$3.4 High: -$3.4 avg. -39.91% |
Operating Expenses
% change YoY
| $83.68M N/A | $131.29M 56.88% | $219.83M 67.43% | Avg: $11.63M Low: $11.63M High: $11.63M avg. -94.70% | Avg: $711.50M Low: $711.50M High: $711.50M avg. 6013.18% | Avg: $1.97B Low: $1.97B High: $1.97B avg. 177.02% | Avg: $2.02B Low: $2.02B High: $2.02B avg. 2.63% |
FAQ
What is Inhibrx Biosciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -2.53% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -290.79M, average is -360.58M and high is -174.85M.
What is Inhibrx Biosciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1550.91% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $1.99M, average is $1.99M and high is $1.99M.
What is Inhibrx Biosciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 3.33% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$6.17, average is -$4.94 and high is $-3.71.